News + Media

IPSEN Transparency

Press Contact

For inquiries, please send an email.


OctreoPharm Sciences GmbH: Annual Report

Berlin, 30th June 2016: OctreoPharm Science GmbH is a subsidiary of the Ipsen group who is a member of the EFPIA (European Federation of Pharmaceutical Industries and Associations).

Ipsen agreed on the EFPIA Disclosure Code (June 2013), which requires the public disclosure of payments to healthcare professionals (HCPs) and healthcare organisations (HCOs) starting 2016 (for payments made in 2015).

The disclosures include transfers of value made for activities such as research and educational grants to healthcare organisations as well as transfers of value to healthcare professionals such as speaker fees, consultancy activities and advisory boards.

OctreoPharm Science GmbH Transfer of Value to HCPs and HCOs are included in the transparency reporting of the respective Ipsen affiliates.

The reporting period is the expired calendar year. Please find the links to Ipsen’s transparency reports.

OctreoPharm Sciences GmbH: Annual Report on IPSEN Transparency and Trust


Previous news


Press Release of IBB Beteiligungsgesellschaft mbH and OctreoPharm Sciences GmbH, 06|2015

IPSEN has closed acquisition of OctreoPharm Sciences GmbH


Press Release of OctreoPharm Sciences GmbH, 16.10.2014

OctreoPharm Sciences Gets FDA Orphan Drug Designation for Management of Neuroendocrine Tumors


Press Release of Eckert & Ziegler AG, Berlin, 01.07.2014

First patient enrolment for SOMscan®


News of OctreoPharm Sciences | Berlin, 30.06.2014

First patient enrolment for SOMscan®


Press Release of Eckert & Ziegler AG | Berlin, 27.02.2014

Rare Disease Day: development candidate SOMscan® receives orphan drug status


Press Release 1 | 2014 | Berlin, 29.01.2014

OctreoPharm Sciences GmbH receives EMA Orphan Drug Designation for OPS202 (SOMscan®), a next generation antagonistic peptide for the Management of Neuroendocrine Tumors